Minnelide
Based on 3 publication(s) in Google Scholar
Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 1254702-87-8
- Formula: C21H25Na2O10P
- Molecular Weight:514.37
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Minnelide
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
WB
-
In Vivo Efficacy Study
-
In Vivo Imaging
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PANC-1 | IC50 |
0.2 μM
Compound: 8h
|
Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay
Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 33289552] |
Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Pancreatic cancer cell line: S2-013, MIA PaCa-2, S2-VP10, and Panc-1 cells
-
Concentration:0.100 nM, 200 nM
-
Incubation Time:48 hours
-
Result:Decreased cell viability of in vitro.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice[2]
-
Dosage:0.1-0.6 mg/kg
-
Administration:Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
-
Result:Prevented pancreatic tumor growth in vivo.
-
Animal Model:Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice[2]
-
Dosage:0.42 mg/kg
-
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
-
Result:Prevented extensive spread from the primary site of injection.
-
Animal Model:Human pancreatic cancer xenografts in SCID mice[2]
-
Dosage:0.21 mg/kg, 0.42 mg/kg
-
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
-
Result:Reduced tumor burden in human xenografts from patients.
Chemical Information
-
CAS No. 1254702-87-8
-
Appearance Solid
-
Molecular Weight 514.37
-
Formula C21H25Na2O10P
-
Color White to off-white
-
SMILES
C[C@@]12[C@@]34[C@]([C@@H]5C[C@@]1([H])C6=C(C(OC6)=O)CC2)(O5)[C@@H]([C@](O7)(C(C)C)[C@@H]7[C@@H]3O4)OCOP(O[Na])(O[Na])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Clin Invest
Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model. [Abstract]2026 Jun 16:e202218. PMID: 42302177 -
Phytomedicine
2024 May 11:130:155724. PMID: 38759317 -
Res Sq
Dual activity of Minnelide chemosensitize basal/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment. [Abstract]2024 Feb 22:rs.3.rs-3959342. PMID: 38464167
Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]
Human breast cancer cell lines, MDA-MB231, Sum159, ZR75–1, MCF7 AND murine breast cancer cell lines, EMT6, E00771, AT3 and 4T1 were incubated with indicated doses of Minnelide (0, 25, 50, 75, 100 μM) for 48 hours and cell viability was measured by MTT assay.
Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]
Breast cancer cell lines, MDA-MB-231 and MCF7 were incubated with indicated doses of Minnelide (0, 25, 50, 75 μM) for 48 hours and apoptotic cell death and CSC population was evaluated by flow cytometer.
Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]
Protein expression of HSP70/72, A20, Vimentin, MYC and BRD4 was shown in human MDA-MB-231 and murine 4T1 and EMT6 cell lines treated with increased dose of Minnelide in the presence and absence of recombinant human TGFβ.
Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]
Size of primary tumors and their weights at the end point of the experiment treated with single Minnelide (0.5 mg/kg).
Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]
Minnelide (0.5 mg/kg) alone significantly reduced the relapse after surgery, and it eliminated all residual tumors when combined with CTX. D. Survival rates of 4T1 tumor bearing mice before and after the resections.
Solvent & Solubility
H2O : 100 mg/mL (194.41 mM; Need ultrasonic)
DMSO : 16.67 mg/mL (32.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Noel P, et al. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341. [Content Brief]
[2]. Chugh R, et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.9441 mL | 9.7206 mL | 19.4413 mL | 48.6031 mL |
| 5 mM | 0.3888 mL | 1.9441 mL | 3.8883 mL | 9.7206 mL | |
| 10 mM | 0.1944 mL | 0.9721 mL | 1.9441 mL | 4.8603 mL | |
| 15 mM | 0.1296 mL | 0.6480 mL | 1.2961 mL | 3.2402 mL | |
| 20 mM | 0.0972 mL | 0.4860 mL | 0.9721 mL | 2.4302 mL | |
| 25 mM | 0.0778 mL | 0.3888 mL | 0.7777 mL | 1.9441 mL | |
| 30 mM | 0.0648 mL | 0.3240 mL | 0.6480 mL | 1.6201 mL | |
| H2O | 40 mM | 0.0486 mL | 0.2430 mL | 0.4860 mL | 1.2151 mL |
| 50 mM | 0.0389 mL | 0.1944 mL | 0.3888 mL | 0.9721 mL | |
| 60 mM | 0.0324 mL | 0.1620 mL | 0.3240 mL | 0.8101 mL | |
| 80 mM | 0.0243 mL | 0.1215 mL | 0.2430 mL | 0.6075 mL | |
| 100 mM | 0.0194 mL | 0.0972 mL | 0.1944 mL | 0.4860 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Minnelide Related Classifications
HY-124584 Related Classifications
Powered by Bioz